Takanawa Pharma
We develop projects, provide advisory and licensing
Pharma Team
Dr. Kaoru Nozu
Executive Representative, Pharmaceutical
47 years experience in the Japanese pharma market
14 years experience in the Japanese market
Dr. Katsushige Gomi
Scientific Director, Pharmaceutical
41 years experience in the Japanese pharma market
Masakazu Sano
Head of Business Development, Pharma
40 years experience in the Japanese pharma market
Hildur Jónsdóttir
Manager, Pharmaceutical
9 years experience in the pharma market
Jean-Pierre Fere
Advisor, Pharmaceutical
46 years experience in the Japanese pharma market
Why work with us?
Experience
Seasoned pharmaceutical industry specialists, with extensive global business experience.
Network
Strong network among the top management of the leading pharmaceutical companies in Japan.
Track Record
Strong track record in pharmaceuticals and health care products. For example M&A, JV, licensing and partnering.
Science Background
Our team members have solid science know-how through decades of pharmaceutical research and development.
KOL Connections
Strong connections with pharmaceutical related key opinion leaders (KOLs) in Japan, especially in the area of oncology.
Active Participation
Active participation in leading industry bodies such as the Japan Pharma Manufacturers Association and the Japan Pharma Licensing Association.
Track Record
2023: Licensing
Takanawa finalized a $221 m. licensing agreement between Gi-Innovation, Korean pharma company, and Maruho, a Japanese pharma company
2020: Licensing
Takanawa finalized a $510 m. licensing agreement between a US pharma company and a Japanese pharma company
2020: Corporate Social Responsibility (CSR)
Takanawa supported and facilitated Avigan (Favipiravir) from Fujifilm to Iceland in the fight against Covid-19. More information can be seen here.
2018: Acquisition
Takanawa participated in acquisition, with industry specialists, financial experts and a strong group of investors, of Actavis' manufacturing site in Iceland, owned by Teva, and established a new pharma company, Coripharma. Takanawa is a shareholder in the company.
2018: Licensing
Takanawa finalized a partnership agreement between Enzymatica AB and a large Japanese pharmaceutical company on the product ColdZyme, a medical device.
Past Projects
By Takanawa's team members in their prior positions
JV
For Actavis, coordinated and facilitated a JV with Aska Pharmaceutical, a Takeda Group company.
Partnership: Oncology
For Actavis, coordinated the establishment of its Japan oncology business, camptothecin, epirubicin, gemcitabine, with Nippon Kayaku, Taiho and Sawai.
Licensing: Oncology
For Sanofi, coordinated evaluation and negotiated the in-licensing of the global leading oncology product camptothecin from Yakult for the European market.
Licensing: Oncology
For Sanofi, coordinated evaluation and negotiated the in-licensing of G-CSF from Chugai for the European market, which led to the establishment of a JV.
Licensing: Oncology
For Yakult, negotiated the in-licensing of G-CSF from Kyowa Hakko Kirin, for the Japanese market.
Licensing: Oncology
For Sanofi, lead the negotiation of the out-licensing of the global leading oncology product docetaxel to Chugai for the Japanese market.
Clinical study: Oncology
For Kyowa Kirin, project read preclinical studies of vinorelbine, for lung/breast cancer, from Pierre Fabre.
Medical affairs: Oncology
For Kyowa Kirin, managed medical affairs of the oncology product 5-FU, which was launched in Japan.
R&D and marketing: Oncology
For Yakult, involved in R&D and marketing of irinotecan, which was launched in Japan.
R&D and marketing: Oncology
For Yakult, involved in R&D and marketing of oxaliplatin, which was launched in Japan.
Co-development and co-promotion: CNS
For Sanofi, lead the negotiation of co-R&D/promotion with Chugai of a CNS product, zopiclone, a hypnotic agent used in the treatment of insomnia, for Japan.
Licensing: CNS
For Sanofi, lead the negotiation of the licensing of a CNS product, zolpidem, that increases GABA inhibitory effects leading to sedation, to Astellas for Japan.
Licensing: CNS
For Kyowa Kirin, involved in the licensing of a CNS product, SSRI, which increases levels of serotonin in the brain, and was launched in Japan.
Global Development: CNS/Cardiovascular:
For Kyowa Kirin, involved in global devel. of istradefylline, parkinson’s disease drug, MOA of adenosine A2a antagonist, for Japan & USA.
R&D: Cardiovascular
For Kaken, involved in the R&D of an anti-hypertensive drug, beta-blocker, launched in Japan.
Licensing: Cardiovascular
For Sanofi, lead the negotiation of the out-licensing of the cardiovascular product, acetanol, β1-receptor antagonist, to Chugai for the Japanese market.
Licensing: Cardiovascular
For Sanofi, lead the negotiation of the out-licensing of a cardiovascular product, antiplatelet agent, to Daiichi-Sankyo for the Japanese market.
The logos are used only for illustrative purposes. They are the property of those companies and should not be viewed as representing current relations with Takanwa Pharma or as a indirect or direct endorsement of those companies.
